2024
PD-1 defines a distinct, functional, tissue-adapted state in Vδ1+ T cells with implications for cancer immunotherapy
Davies D, Kamdar S, Woolf R, Zlatareva I, Iannitto M, Morton C, Haque Y, Martin H, Biswas D, Ndagire S, Munonyara M, Gillett C, O’Neill O, Nussbaumer O, Hayday A, Wu Y. PD-1 defines a distinct, functional, tissue-adapted state in Vδ1+ T cells with implications for cancer immunotherapy. Nature Cancer 2024, 5: 420-432. PMID: 38172341, PMCID: PMC10965442, DOI: 10.1038/s43018-023-00690-0.Peer-Reviewed Original ResearchConceptsCheckpoint inhibitionPD-1T cellsProgrammed cell death protein 1Cell death protein 1PD-1 expressionResponse to TCR signalingPD-1 engagementT cell recognitionCancer immunotherapyTCR signalingTranscriptomic programsProtein 1CancerFunctional relevanceCellsImmunotherapyNeoantigensMelanomaPatientsOncology
2023
Quantifying the impact of immunotherapy on RNA dynamics in cancer
Usaite I, Biswas D, Dijkstra K, Watkins T, Pich O, Puttick C, Angelova M, Thakkar K, Hiley C, Birkbak N, Kok M, Zaccaria S, Wu Y, Litchfield K, Swanton C, Kanu N. Quantifying the impact of immunotherapy on RNA dynamics in cancer. Journal For ImmunoTherapy Of Cancer 2023, 11: e007870. PMID: 37914385, PMCID: PMC10626770, DOI: 10.1136/jitc-2023-007870.Peer-Reviewed Original ResearchMeSH KeywordsBreast NeoplasmsCombined Modality TherapyFemaleHumansImmunotherapyMelanomaTumor MicroenvironmentConceptsCheckpoint inhibitorsCheckpoint inhibitor treatmentBreast cancerOn-therapyImmune microenvironmentPre-therapyCancer typesPatients treated with checkpoint inhibitorsCheckpoint inhibitor therapyImpact of immunotherapyCancer immune microenvironmentSolid tumor typesMechanism of sensitizationClinical responseCombination therapyTumor typesIO targetsResponse ratePatientsBreastCancerImmunotherapyMelanomaMeta-analysesTherapy
2020
Metastasis and Immune Evasion from Extracellular cGAMP HydrolysisENPP1, a Therapeutic Target in Chromosomally Unstable Tumors
Li J, Duran M, Dhanota N, Chatila W, Bettigole S, Kwon J, Sriram R, Humphries M, Salto-Tellez M, James J, Hanna M, Melms J, Vallabhaneni S, Litchfield K, Usaite I, Biswas D, Bareja R, Li H, Martin M, Dorsaint P, Cavallo J, Li P, Pauli C, Gottesdiener L, DiPardo B, Hollmann T, Merghoub T, Wen H, Reis-Filho J, Riaz N, Su S, Kalbasi A, Vasan N, Powell S, Wolchok J, Elemento O, Swanton C, Shoushtari A, Parkes E, Izar B, Bakhoum S. Metastasis and Immune Evasion from Extracellular cGAMP HydrolysisENPP1, a Therapeutic Target in Chromosomally Unstable Tumors. Cancer Discovery 2020, 11: 1212-1227. PMID: 33372007, PMCID: PMC8102348, DOI: 10.1158/2159-8290.cd-20-0387.Peer-Reviewed Original ResearchConceptsChromosomally unstable tumorsAnti-PD-1/PD-L1 treatmentResponse to immune checkpoint blockadeReduced immune cell infiltrationUnstable tumorsGeneration of extracellular adenosineCancer cells to immune cellsImmune-suppressive pathwaysImmune checkpoint blockadeResistance to immunotherapyTumor immune infiltrationImmune cell infiltrationEvading immune surveillanceMetastatic cancer cellsCGAS-STING innate immune pathwayExtracellular cGAMPCheckpoint blockadeInnate immune pathwaysTumor inflammationImmune surveillanceExtracellular adenosineImmune infiltrationIncreased metastasisImmune cellsCell infiltration